Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iophendylate SCHEMBL15532920 | 0.92 | MAPT (0.41) | CYP4F2CYP4A11KMT2AMEN1ALDH1A1 | |
| SCHEMBL7708867 | 0.80 | CYP3A4 (0.53) | CYP4F2CYP4A11TDP1ALDH1A1CYP3A4 | |
| SCHEMBL31615146 | 0.79 | ALDH1A1 (0.44) | TDP1KMT2AMEN1ALDH1A1ALOX15 | |
| SCHEMBL8902332 | 0.79 | ALOX15 (0.55) | TDP1KMT2AMEN1ALDH1A1ALOX15 | |
| SCHEMBL3936803 | 0.78 | CYP4F2 (0.46) | CYP4F2CYP4A11TDP1KMT2AALDH1A1 | |
| SCHEMBL492664 | 0.78 | CYP4F2 (0.46) | CYP4F2CYP4A11TDP1KMT2AALDH1A1 | |
| SCHEMBL25969333 | 0.78 | CYP4F2 (0.43) | CYP4F2CYP4A11TDP1KMT2AMEN1 | |
| SCHEMBL5962655 | 0.77 | NAMPT (0.41) | CYP4F2CYP4A11TDP1KMT2AMEN1 | |
| SCHEMBL1263477 | 0.77 | CYP4Z1 (0.58) | CYP4F2CYP4A11TDP1ALDH1A1ALOX15 | |
| SCHEMBL9559017 | 0.77 | CYP4Z1 (0.58) | CYP4F2CYP4A11TDP1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 921 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170280-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| US-20250170279-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| WO-2025052207-A1 | DEVICES TO BE IMPLANTED INTO THE HUMAN BODY AND METHOD FOR THEIR REALIZATION | TECRES S.P.A. (IT) | 2025-03-13 | — | — | WO | claimed |
| US-20230414836-A1 | DEVICES TO BE IMPLANTED INTO THE HUMAN BODY | TECRES S.P.A. (IT) | 2023-12-28 | — | — | US | claimed |
| WO-2021238893-A1 | EFFICIENT AND EFFECTIVE TISSUE CLEARING AGENTS AND THEIR COMPOSITIONS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2021-12-02 | — | — | WO | claimed |
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2021-05-20 | — | — | US | claimed |
| US-20200397926-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2020-12-24 | — | — | US | claimed |
| EP-3744317-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Inno Medicine Co., Ltd. (CN) | 2020-12-02 | — | — | EP | claimed |
| US-10600524-B2 | Radiation protection device and methods thereof | STEMRAD LTD. (IL) | 2020-03-24 | — | — | US | claimed |
| EP-3610859-A1 | CERASOME DELIVERY SYSTEM FOR USE IN TARGETED ACTIVATION OF CD44 MOLECULE, PREPARATION METHOD THEREFOR AND USE | Beijing Inno Medicine Co., Ltd. (CN) | 2020-02-19 | — | — | EP | claimed |
| EP-0414806-A1 | HIGH RATIO ACTIVE AGENT:LIPID COMPLEX. | LIPOSOME CO INC (US) | 1991-03-06 | — | — | EP | claimed |
| EP-0165994-B1 | CONTRAST AGENTS AND METHOD OF USE THEREOF | RUBIN, Daniel Lee (US) | 1990-07-18 | — | — | EP | claimed |
| WO-1989011272-A1 | HIGH RATIO ACTIVE AGENT:LIPID COMPLEX | THE LIPOSOME COMPANY, INC. (US) | 1989-11-30 | — | — | WO | claimed |
| EP-0165630-B1 | METHOD OF PREPARING A CHLORINATED, BROMINATED, RADIOBROMINATED, IODINATED AND/OR RADIOIODINATED, AROMATIC OR HETEROAROMATIC COMPOUND, AS WELL AS A KIT FOR PREPARING A DIAGNOSTIC COMPOSITION ON THE BASIS OF THIS COMPOUND | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1989-10-18 | — | — | EP | claimed |
| CN-86107191-A | Vascular occlusive agent (TH glue) | — | 1988-04-27 | — | — | CN | claimed |
| EP-0165994-A4 | CONTRAST AGENTS AND METHOD OF USE THEREOF. | RUBIN DANIEL LEE | 1986-11-07 | — | — | EP | claimed |
| EP-0165994-A1 | CONTRAST AGENTS AND METHOD OF USE THEREOF. | RUBIN DANIEL LEE | 1986-01-02 | — | — | EP | claimed |
| EP-0165630-A2 | Method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radioiodinated, aromatic or heteroaromatic compound, as well as a kit for preparing a diagnostic composition on the basis of this compound | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1985-12-27 | — | — | EP | claimed |
| WO-1985003004-A1 | CONTRAST AGENTS AND METHOD OF USE THEREOF | RUBIN DANIEL LEE | 1985-07-18 | — | — | WO | claimed |
| US-4192859-A | MEDICAL DIAGNOSIS USING X-RAYS | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | CD44, LDLR, PLAUR | CYP4F2 4744/4885CYP4A11 3295/4885TDP1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.